Clinical trial
Safety Study of Anti-IgE Immunotherapy in Allergic Patients
NCT00439621 · Resistentia Pharmaceuticals AB, Industry · Completed
Key facts
| NCT number | NCT00439621 |
|---|---|
| Title | Safety Study of Anti-IgE Immunotherapy in Allergic Patients |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients |
| Lead sponsor | Resistentia Pharmaceuticals AB, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Biological |
| Interventions | RP 01 |
| Enrollment | 42 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Feb 23, 2007 |
| Last update posted | Aug 18, 2008 |
| Countries | New Zealand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: